vs
ARKO Corp.（ARKO）与博士伦健康（BHC）财务数据对比。点击上方公司名可切换其他公司
博士伦健康的季度营收约是ARKO Corp.的1.6倍（$2.8B vs $1.8B），ARKO Corp.净利率更高（0.1% vs -3.7%，领先3.8%），博士伦健康同比增速更快（9.3% vs -9.9%），博士伦健康自由现金流更多（$403.0M vs $14.9M），过去两年博士伦健康的营收复合增速更高（14.0% vs -7.0%）
ARKO Corp.是美国知名的便利店与燃油零售运营商，业务覆盖美国多个州，面向消费者销售生鲜食品、饮品、日用必需品等商品，同时提供燃油零售及面向商业合作伙伴的批发配送服务。
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
ARKO vs BHC — 直观对比
营收规模更大
BHC
是对方的1.6倍
$1.8B
营收增速更快
BHC
高出19.2%
-9.9%
净利率更高
ARKO
高出3.8%
-3.7%
自由现金流更多
BHC
多$388.1M
$14.9M
两年增速更快
BHC
近两年复合增速
-7.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $2.8B |
| 净利润 | $1.9M | $-103.0M |
| 毛利率 | — | — |
| 营业利润率 | 1.2% | 17.0% |
| 净利率 | 0.1% | -3.7% |
| 营收同比 | -9.9% | 9.3% |
| 净利润同比 | 180.9% | -205.1% |
| 每股收益（稀释后） | $0.01 | $-0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARKOBHC
| Q4 25 | $1.8B | $2.8B | ||
| Q3 25 | $2.0B | $2.7B | ||
| Q2 25 | $2.0B | $2.5B | ||
| Q1 25 | $1.8B | $2.3B | ||
| Q4 24 | $2.0B | $2.6B | ||
| Q3 24 | $2.3B | $2.5B | ||
| Q2 24 | $2.4B | $2.4B | ||
| Q1 24 | $2.1B | $2.2B |
净利润ARKOBHC
| Q4 25 | $1.9M | $-103.0M | ||
| Q3 25 | $13.5M | $179.0M | ||
| Q2 25 | $20.1M | $148.0M | ||
| Q1 25 | $-12.7M | $-58.0M | ||
| Q4 24 | $-2.3M | $98.0M | ||
| Q3 24 | $9.7M | $-85.0M | ||
| Q2 24 | $14.1M | $10.0M | ||
| Q1 24 | $-594.0K | $-64.0M |
营业利润率ARKOBHC
| Q4 25 | 1.2% | 17.0% | ||
| Q3 25 | 1.8% | 23.1% | ||
| Q2 25 | 2.8% | 17.5% | ||
| Q1 25 | -0.6% | 12.2% | ||
| Q4 24 | 0.7% | 21.8% | ||
| Q3 24 | 1.8% | 12.7% | ||
| Q2 24 | 1.8% | 16.2% | ||
| Q1 24 | -0.2% | 13.1% |
净利率ARKOBHC
| Q4 25 | 0.1% | -3.7% | ||
| Q3 25 | 0.7% | 6.7% | ||
| Q2 25 | 1.0% | 5.8% | ||
| Q1 25 | -0.7% | -2.6% | ||
| Q4 24 | -0.1% | 3.8% | ||
| Q3 24 | 0.4% | -3.4% | ||
| Q2 24 | 0.6% | 0.4% | ||
| Q1 24 | -0.0% | -3.0% |
每股收益（稀释后）ARKOBHC
| Q4 25 | $0.01 | $-0.30 | ||
| Q3 25 | $0.10 | $0.48 | ||
| Q2 25 | $0.16 | $0.40 | ||
| Q1 25 | $-0.12 | $-0.16 | ||
| Q4 24 | $-0.03 | $0.24 | ||
| Q3 24 | $0.07 | $-0.23 | ||
| Q2 24 | $0.11 | $0.03 | ||
| Q1 24 | $-0.02 | $-0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $311.5M | $1.3B |
| 总债务越低越好 | $912.1M | $20.8B |
| 股东权益账面价值 | $267.2M | $-554.0M |
| 总资产 | $3.5B | $26.4B |
| 负债/权益比越低杠杆越低 | 3.41× | — |
8季度趋势，按日历期对齐
现金及短期投资ARKOBHC
| Q4 25 | $311.5M | $1.3B | ||
| Q3 25 | $313.2M | $1.3B | ||
| Q2 25 | $299.7M | $1.7B | ||
| Q1 25 | $271.1M | $1.1B | ||
| Q4 24 | $267.1M | $1.2B | ||
| Q3 24 | $296.8M | $719.0M | ||
| Q2 24 | $236.5M | $595.0M | ||
| Q1 24 | $189.1M | $733.0M |
总债务ARKOBHC
| Q4 25 | $912.1M | $20.8B | ||
| Q3 25 | $911.6M | $21.0B | ||
| Q2 25 | $916.4M | $21.7B | ||
| Q1 25 | $880.1M | $21.5B | ||
| Q4 24 | $881.0M | $21.6B | ||
| Q3 24 | $884.7M | $21.5B | ||
| Q2 24 | $889.9M | $21.7B | ||
| Q1 24 | $885.0M | $22.1B |
股东权益ARKOBHC
| Q4 25 | $267.2M | $-554.0M | ||
| Q3 25 | $273.1M | $-565.0M | ||
| Q2 25 | $264.8M | $-764.0M | ||
| Q1 25 | $255.2M | $-1.2B | ||
| Q4 24 | $276.9M | $-1.3B | ||
| Q3 24 | $280.0M | $-1.2B | ||
| Q2 24 | $273.1M | $-1.2B | ||
| Q1 24 | $261.2M | $-1.1B |
总资产ARKOBHC
| Q4 25 | $3.5B | $26.4B | ||
| Q3 25 | $3.6B | $26.8B | ||
| Q2 25 | $3.6B | $27.3B | ||
| Q1 25 | $3.6B | $26.4B | ||
| Q4 24 | $3.6B | $26.5B | ||
| Q3 24 | $3.7B | $26.5B | ||
| Q2 24 | $3.7B | $26.5B | ||
| Q1 24 | $3.6B | $26.9B |
负债/权益比ARKOBHC
| Q4 25 | 3.41× | — | ||
| Q3 25 | 3.34× | — | ||
| Q2 25 | 3.46× | — | ||
| Q1 25 | 3.45× | — | ||
| Q4 24 | 3.18× | — | ||
| Q3 24 | 3.16× | — | ||
| Q2 24 | 3.26× | — | ||
| Q1 24 | 3.39× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.6M | $495.0M |
| 自由现金流经营现金流 - 资本支出 | $14.9M | $403.0M |
| 自由现金流率自由现金流/营收 | 0.8% | 14.4% |
| 资本支出强度资本支出/营收 | 1.7% | 3.3% |
| 现金转化率经营现金流/净利润 | 23.98× | — |
| 过去12个月自由现金流最近4个季度 | $65.3M | $1.0B |
8季度趋势，按日历期对齐
经营现金流ARKOBHC
| Q4 25 | $44.6M | $495.0M | ||
| Q3 25 | $49.4M | $405.0M | ||
| Q2 25 | $55.2M | $289.0M | ||
| Q1 25 | $43.4M | $211.0M | ||
| Q4 24 | $22.7M | $601.0M | ||
| Q3 24 | $109.2M | $405.0M | ||
| Q2 24 | $77.2M | $380.0M | ||
| Q1 24 | $12.8M | $211.0M |
自由现金流ARKOBHC
| Q4 25 | $14.9M | $403.0M | ||
| Q3 25 | $24.5M | $314.0M | ||
| Q2 25 | $9.8M | $190.0M | ||
| Q1 25 | $16.0M | $96.0M | ||
| Q4 24 | $-13.4M | $495.0M | ||
| Q3 24 | $79.9M | $334.0M | ||
| Q2 24 | $57.9M | $302.0M | ||
| Q1 24 | $-16.5M | $129.0M |
自由现金流率ARKOBHC
| Q4 25 | 0.8% | 14.4% | ||
| Q3 25 | 1.2% | 11.7% | ||
| Q2 25 | 0.5% | 7.5% | ||
| Q1 25 | 0.9% | 4.2% | ||
| Q4 24 | -0.7% | 19.3% | ||
| Q3 24 | 3.5% | 13.3% | ||
| Q2 24 | 2.4% | 12.6% | ||
| Q1 24 | -0.8% | 6.0% |
资本支出强度ARKOBHC
| Q4 25 | 1.7% | 3.3% | ||
| Q3 25 | 1.2% | 3.4% | ||
| Q2 25 | 2.3% | 3.9% | ||
| Q1 25 | 1.5% | 5.1% | ||
| Q4 24 | 1.8% | 4.1% | ||
| Q3 24 | 1.3% | 2.8% | ||
| Q2 24 | 0.8% | 3.2% | ||
| Q1 24 | 1.4% | 3.8% |
现金转化率ARKOBHC
| Q4 25 | 23.98× | — | ||
| Q3 25 | 3.67× | 2.26× | ||
| Q2 25 | 2.75× | 1.95× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.13× | ||
| Q3 24 | 11.28× | — | ||
| Q2 24 | 5.49× | 38.00× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARKO
| Fuel Products | $1.4B | 79% |
| Merchandise Products | $338.1M | 19% |
| Other Product | $33.6M | 2% |
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
